Monday, November 30, 2020 4:42:13 PM
They can start pre-screening today. If qualified, they will call back tomorrow after Ino green-lights. The participant will come in for a blood draw and COVID-19 viral test. The sample will be sent to a PCR lab. After result comes back negative, they will schedule the participant to come in to get first shot. This site will recruit 40 ppl. Recruiting will end 12/15/20 which synchronizes with China P2 trial. This means all participants will have first shot by 12/15/20. Then the study will be updated with “Active, not Recruiting”.
https://clinicaltrials.gov/ct2/show/NCT04642638#contacts
San Diego, California, United States, 92108
Contact: Prinicipal Investigator Patrick Yassini pyassini@optimalsites.net
5920 Friars Rd UNIT 200, San Diego, CA 92108
Located in: PARK PLACE PLAZA
Open · Closes 5PM
(619) 291-2845
Official-INO-4800-P2-start-in-China-Recruiting-11/27-12/15, 640 ppl, 18-85 yrs old
Registration number:
ChiCTR2000040146
Date of Last Refreshed on:
2020-11-22
Date of Registration:
2020-11-22
Registration Status:
Prospective registration
Public title:
A Phase II, Randomized, Double-blinded, Placebo-controlled, Dose-finding Clinical Study to Evaluate the Safety and Immunogenicity of Different Doses of INO-4800 Administered Intradermally Followed by Electroporation in Healthy Adult and Elderly Volunteers
Objectives of Study:
Primary objectives: ? To evaluate the safety and tolerability of INO-4800 at different dose levels in healthy subjects (= 18 and < 60 years old as well as = 60 and = 85 years old); ? To evaluate the humoral immune response of INO-4800 at different doses in healthy subjects (= 18 and < 60 years old as well as = 60 and = 85 years old). Secondary objective: ? To evaluate the duration of humoral response of INO-4800 at different doses in healthy subjects at different ages ((= 18 and < 60 years old as well as = 60 and = 85 years old). Exploratory objective: ? To evaluate the cellular immune response of INO-4800 at different doses in healthy subjects ((= 18 and < 60 years old as well as = 60 and = 85 years old).
Study execute time:
From 2020-11-27 To 2020-12-15
Recruiting time:
From 2020-11-27 To 2020-12-15
Group:2
Sample size:640
Country: China
Province:Jiangsu
Hospital: Danyang City Center for Disease Control and Prevention
http://www.chictr.org.cn/showprojen.aspx?proj=64452
Recent INO News
- INOVIO to Present at Upcoming Scientific Conference • PR Newswire (US) • 09/17/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 10:22:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:06:54 AM
- INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 • PR Newswire (US) • 07/25/2024 08:05:00 PM
- INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway • PR Newswire (US) • 07/11/2024 12:00:00 PM
- INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer • PR Newswire (US) • 07/02/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 07/01/2024 08:00:00 PM
- INOVIO Added to Russell 2000® Index Effective July 1, 2024 • PR Newswire (US) • 07/01/2024 12:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. • PR Newswire (US) • 06/04/2024 12:00:00 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/31/2024 08:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:49:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:13:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:10:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM